Pharmacokinetic and pharmacodynamic properties of SOL1: A novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme

Life Sciences

Volumn 91, Issue 13-14, 2012, Pages 587-592

  Nelissen, J ^a   Lemkens, P ^a   Sann, H ^b   Bindl, M ^b   Bassissi, F ^b   Jasserand, D ^b   De Mey, J G R ^a   Janssen, B J A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Calcitonin gene related peptide; Endothelin converting enzyme; Kidney; Metalloproteases; Neutral endopeptidase

Indexed keywords

BIG ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; SOL1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME INHIBITION; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; MOUSE; NONHUMAN; RAT; SINGLE DRUG DOSE;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BENZAZEPINES; BLOOD PRESSURE; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERTENSION; INHIBITORY CONCENTRATION 50; MALE; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; NEPRILYSIN; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SODIUM CHLORIDE, DIETARY; TISSUE DISTRIBUTION;

MUS; RATTUS; RODENTIA;

EID: 84867581900     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.01.015     Document Type: Conference Paper

References (16)

1. M. Brands, J.K. Erguden, K. Hashimoto, D. Heimbach, T. Krahn, and C. Schroder Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation ChemMedChem 1 2006 96 105
2. R. Corder, and J.R. Vane Radioimmunoassay evidence that the pressor effect of big endothelin-1 is due to local conversion to endothelin-1 Biochem Pharmacol 49 1995 375 380
3. N. Dhaun, and D.J. Webb Dual endothelin-converting enzyme/neutral endopeptidase inhibition: a novel treatment for renovascular hypertension beyond blood pressure lowering? Hypertension 57 2011 667 669
4. R.G. Goldie, P.G. Knott, M.J. Carr, D.W. Hay, and P.J. Henry The endothelins in the pulmonary system Pulm Pharmacol 9 1996 69 93
5. K. Hisaki, Y. Matsumura, S. Nishiguchi, K. Fujita, M. Takaoka, and S. Morimoto Endothelium-independent pressor effect of big endothelin-1 and its inhibition by phosphoramidon in rat mesenteric artery Eur J Pharmacol 241 1993 75 81
6. A.Y. Jeng, P. Mulder, A.L. Kwan, and B. Battistini Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications Can J Physiol Pharmacol 80 2002 440 449
7. P. Kalk, Y. Sharkovska, E. Kashina, K. von Websky, K. Relle, and T. Pfab Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner Hypertension 57 2011 755 763
8. N.S. Kirkby, P.W. Hadoke, A.J. Bagnall, and D.J. Webb The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153 2008 1105 1119
9. D.E. Kohan, N.F. Rossi, E.W. Inscho, and D.M. Pollock Regulation of blood pressure and salt homeostasis by endothelin Physiol Rev 91 2011 1 77
10. M.J. Meens, M.G. Compeer, T.M. Hackeng, M.A. van Zandvoort, B.J. Janssen, and J.G. De Mey Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ET(A)-receptor complexes PLoS One 5 2010 e10917
11. M.J. Meens, N.J. Mattheij, J. Nelissen, P. Lemkens, M.G. Compeer, and B.J. Janssen Calcitonin gene-related peptide terminates long-lasting vasopressor responses to endothelin 1 in vivo Hypertension 58 2011 99 106
12. J. Nelissen, B. Heijnen, P. Lemkens, J Debets, H. Van Essen, and J. De Mey Endothelin-1 and Calcitonin Gene Related Peptide contribute to developing hypertension in young SHR Acta Physiol 203 Supplement 687 2011 O-08
13. B.E. Padilla, G.S. Cottrell, D. Roosterman, S. Pikios, L. Muller, and M. Steinhoff Endothelin-converting enzyme-1 regulates endosomal sorting of calcitonin receptor-like receptor and beta-arrestins J Cell Biol 179 2007 981 997
14. Y. Sharkovska, P. Kalk, K. von Websky, K. Relle, T. Pfab, and M. Alter Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage Clin Lab 57 2011 507 515
15. D.H. Wang, and Y. Zhao Increased salt sensitivity induced by impairment of sensory nerves: is nephropathy the cause? J Hypertens 21 2003 403 409
16. C. Wengenmayer, M. Krikov, S. Mueller, K. Lucht, A. Villringer, and B. Hocher Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival Neurol Res 33 2011 201 207